AbbVie
ABBV
4,171 hedge funds and large institutions have $301B invested in AbbVie in 2025 Q4 according to their latest regulatory filings, with 467 funds opening new positions, 1,609 increasing their positions, 1,641 reducing their positions, and 126 closing their positions.
271% more first-time investments, than exits
New positions opened: 467 | Existing positions closed: 126
6% more funds holding
Funds holding: 3,918 → 4,171 (+253)
2.61% more ownership
Funds ownership: 71.99% → 74.6% (+2.6%)
2% more capital invested
Capital invested by funds: $294B → $301B (+$6.8B)
1% less call options, than puts
Call options by funds: $2.85B | Put options by funds: $2.87B
2% less repeat investments, than reductions
Existing positions increased: 1,609 | Existing positions reduced: 1,641
8% less funds holding in top 10
Funds holding in top 10: 218 → 200 (-18)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$1.53B |
| 2 |
BlackRock
New York
|
+$1.18B |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$1,000M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$955M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$691M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$943M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$540M |
| 3 |
Millennium Management
New York
|
-$455M |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$409M |
| 5 |
Morgan Stanley
New York
|
-$367M |
ABBV Hedge Fund Activity: Q4 2025 in Review
4,171 of the 8,284 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q4 2025, worth a combined $301B — up 2.3% from $294B a quarter earlier.
Buyers outnumbered sellers: 467 funds opened new ABBV positions and 126 closed out — a net gain of 341 holders — while 1,609 added to existing stakes and 1,641 trimmed.
The largest buyer was Capital World Investors, adding an estimated $1.53B. The largest seller was JP Morgan Chase, cutting an estimated $943M.
- 4,171 institutional investors held AbbVie (ABBV) as of Q4 2025, up from 3,918 in Q3 2025.
- Funds reported $301B of AbbVie stock for Q4 2025, up 2.3% quarter-over-quarter.
- 467 funds opened new AbbVie positions in Q4 2025 and 126 closed out, a net change of +341 holders.
- The largest AbbVie buyer in Q4 2025 was Capital World Investors, an estimated $1.53B added.
- The largest AbbVie seller in Q4 2025 was JP Morgan Chase, an estimated $943M sold.
Based on aggregated 13F filings for Q4 2025.